Evidence map›Paper›PMID 27101015›Full record

ReviewCurrent hematologic malignancy reports2016

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.

Ajoy Dias, Saad J Kenderian, Gustavo F Westin, Mark R Litzow

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ajoy DiasDivision of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Saad J KenderianDivision of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Gustavo F WestinDivision of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Mark R LitzowDivision of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Litzow.Mark@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.

Indexed as

AdultAntibodies, MonoclonalAntigens, CD19Antigens, CD20HumansImmunotherapyMolecular Targeted TherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellSialic Acid Binding Ig-like Lectin 2Antibodies, MonoclonalAntigens, CD19Antigens, CD20Receptors, Antigen, T-CellSialic Acid Binding Ig-like Lectin 2Acute lymphoblastic leukemia (ALL)Chimeric antigen receptor T cells (CART)ImmunotherapiesMonoclonal antibodies

Identifiers

PMID27101015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.